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New therapeutic agents are needed in digestive tract tumors. Co-029/tspan8 is a
tetraspanin frequently expressed on human colorectal tumors, In this work, we report
the effects of the monoclonal antibody Ts29.2, targeting Co-029/tspan8, on colorectal
tumor cells in vitro and after implantation in nude mice. HT29, Isreco1 and SW480
colorectal tumor cell lines were used for this study. HT29 has a strong endogenous
expression of Co-029/tspan8, whereas Isreco1 cells don’t express Co-029/tspan8 and
SW480 has only a weak expression. Isreco1 and SW480 were transduced to express
Co-029/tspan8 at the same level as HT29. In order to check the specificity of the
effect of monoclonal antibody Ts29.2, low Co-029/tspan8 expressing SW480 cells were
injected simultaneously with transduced cells in the back, on the left and right sides of
the mice. With an early treatment, Ts29.2 mAb inhibited growth of tumors expressing
Co-029/tspan8 up to 70%, whereas a delayed treatment was less efficient. No effect
of the antibody on cell proliferation or apoptosis induction was detected in vitro. No
increase of activated caspase 3 labeling was observed in vivo and areas occupied by
vessels were not significantly different between treated mice and controls. This suggests
that the action of Ts29.2 is linked neither to cellular toxicity nor to the inhibition of
the previously reported angiogenic properties of Co-029/tspan8. An inhibition of cell
proliferation in vivo is demonstrated by a reduction of the mitotic index in HT29 tumors of
Ts29.2 treated mice. The discrepancy between in vitro and in vivo data on cell proliferation
suggests that the binding of Ts29.2 to tumor cells may modify their response to signals
issued from the microenvironment. Given the restricted pattern of tissue expression
of the tetraspanin Co-029/tspan8, these preliminary results put forth for consideration
the antibody targeting of this tetraspanin in further investigations for therapeutic
applications.
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INTRODUCTION
Colorectal cancer is one of the most frequent tumors world-
wide and one of the leading causes of cancer-related deaths.
Colorectal cancers account for 9% of all cancer related deaths
in the USA. The 5-year relative survival rates of US patients is
64%. At early localized stages (39% of the patients at diagno-
sis), the 5-year survival rate is above 90% but if adjacent organs
or lymph nodes are involved, it drops to 69% and to 12% if the
disease is metastatic (American Cancer Society, 2012). Adjuvant
therapy reduces the risk of relapse but it is only partially effi-
cient and not without adverse effects. For metastatic tumors,
cure expectation remains low even if it has greatly improved in
case of resectable liver metastasis with the combination of more
Abbreviations: mAb, monoclonal antibody; ADCC, antibody dependent cell
cytotoxicity.
effective medical treatment combined with surgery (Bilchik et al.,
2008).
Monoclonal antibodies have come of age as therapeutics in
numerous diseases including cancer. Since the elimination of for-
eign antibodies by the immune system has been largely solved
through humanization of murine antibodies, other problems
remain to be overcome in diverse situations in order to get
the most efficient and tolerated therapeutic drugs. Only a lim-
ited number of mAb are presently approved for therapy of solid
tumors due to several factors, a major barrier being diffusion into
the tumor. The antigenic target is also a matter of concern since
the expression of this antigen may be harmful for the patient if
it is targeted in normal tissues. Therefore, it is preferable that the
antigen is either not expressed in normal tissues or in few tissues
and at a low level as compared to the tumor. It is also of value if the
expression of the antigen correlates positively with the prognosis.
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Monoclonal antibodies are already widely used for treatment
of colorectal cancer. Cetuximab, that targets EGFR, is a func-
tion blocking antibody and it’s in vivo effect is probably linked
to this property. In association with chemotherapy it induces a
prolonged progression free survival whereas no effect on overall
survival has been reported. The efficiency of Cetuximab is ham-
pered by activating mutations of KRAS and BRAF thus limiting
its use (Dahabreh et al., 2011; Lin et al., 2011). Bevacizumab
that targets VGFR, is also efficient in colorectal tumors treat-
ment. However, high blood pressure, diarrhea, mouth sores
and delayed wound healing (Hompes and Ruers, 2011) are
some of Bevacizumab’s side effects while those of cetuximab
include itching, acne-like skin rash and low blood electrolyte
levels.
New antibodies targeting more specifically colorectal tumors
antigens would therefore be of great help. Tetraspanin Co-
029/tspan8 (Zoller, 2009) could be an appropriate target for mAb
therapy in digestive tumors. The expression of this molecule is
restricted to a small number of tissues such as digestive epithe-
lial cells especially in colon and stomach and slightly on biliary
epithelial cells. Its expression has been also reported in tumors
and apart from esophagus, stomach and colorectal cancers, it can
be observed in liver, prostate, ovarian and cervical cancer (Uhlen
et al., 2010). In addition we have shown earlier that the expression
of Co-029/tspan8 is associated with a poor prognosis in colorectal
cancer (Greco et al., 2010). Similar observations have been made
for esophageal (Zhou et al., 2008) and hepatocellular carcinoma
(Kanetaka et al., 2001).
In the present study, we have used a new Co-029/tspan8
mAb produced in our laboratory to demonstrate an in vivo
effect against human tumors engrafted in nude mice and have
compared our observations with previous reports related to the
biology of this tetraspanin.
MATERIALS AND METHODS
CELLS AND CELL CULTURE
The cell lines Isrecol, was initially derived from a primary
human colon cancer (Duke’s C, class III) surgical specimen
(Isreco1) together with cell lines from its corresponding liver
and peritoneal metastases, Isreco2 and Isreco3 (Cajot et al.,
1997). The colorectal carcinoma cell line SW480 and HT29
were purchased from ATCC. The cell lines, were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% FCS, glutamax and antibiotics (all from Invitrogen).
Isreco1 cells harbor a G12D homozygous mutation of KRAS
whereas SW480 and HT29 cells were checked for respectively
the KRAS homozygous G12V mutation and the BRAF V600E
mutation.
LENTIVIRAL VECTORS
The human Co-029/tspan8 cDNA coding sequence was inserted
in the TRIP3-EF1α vectors. Vector particles were produced by
cotransfection of 293T cells by the TRIP3-EF1α-Co029 plas-
mids together with encapsidation and envelope (vesicular stom-
atitis virus) expression plasmids (Greco et al., 2010). Isreco1
cells and SW480 cells were transduced twice with concentrated
lentiviral particles.
ANTIBODIES
The Co-029/tspan8 mAb TS29.2 (IgG2b), not reported before,
was issued from the same fusion as Ts29 (an IgG1 that is now
called Ts29.1) (Greco et al., 2010). Briefly, BALB/c mice were
injected intraperitoneally twice with a mixture of 107 Isreco3
and Lovo cells and a final boost was performed 3 weeks later
with CD9-containing complexes collected by immunoprecipita-
tion from a Brij97 lysate of 109 Isreco3 cells that express strongly
Co-029/tspan8 (Le Naour et al., 2006). Spleen cells were fused
with P3X63AG8 mouse myeloma cells (5 × 107 and 3 × 107 cells
respectively) according to standard techniques and distributed
into 96-well tissue culture plates. After 2 weeks hybridoma culture
supernatants were harvested and tested for Isreco1 and Is1-Co029
staining by indirect immunofluorescence. Positive supernatants
were then further characterized by immunoprecipitation. The
mAb Ts29.2 was purified by MEP Hypercel mixed-mode sor-
bent (Pall France) from ascitic fluids. Purity was checked by gel
electrophoresis and Coomassie blue staining. Using infrared scan-
ning of the gel with Odyssey Infrared Imaging System (LI-COR
Biosciences), the purity was shown to be superior to 90%.
IMMUNOFLUORESCENCE
For flow cytometry analysis of cell surface molecules, cells were
detached using a non-enzymatic solution (Invitrogen), washed
and stained with 10μg/ml of primary antibody. After washes
in culture medium, cells were incubated with 10μg/ml FITC-
labeled secondary antibody (Beckman Coulter), washed again
three times and fixed with 1% formaldehyde in PBS. All incu-
bations were performed for 30min at 4◦C. Analysis of cell-
surface staining was performed with an Accuri C6 flow cytometer
(Becton-Dickinson, San Jose, CA, USA).
IMMUNOPRECIPITATION ANDWESTERN BLOT
Cells were lysed directly in the tissue culture flask (1ml
for a 75-cm2 flask) in lysis buffer (10mM Tris (pH 7.4),
150mM NaCl, 0.02% NaN3, 1mM phenylmethylsulfonyl fluo-
ride, 0.5mg/ml leupeptin, 1mg/ml pepstatin A and 10 kallikrein-
inactivating units/ml aprotinin) containing 1% Triton X-100
(Roche Molecular Biochemicals, Meylan, France). After a 30-min
incubation at 4◦C, the insoluble material was removed by cen-
trifugation at 10,000 g and the cell lysate was precleared overnight
by addition of 0.005 volume of heat-inactivated goat serum
and 0.025 volume of protein G-Sepharose beads (Amersham
Pharmacia Biotech). Proteins were then immunoprecipitated by
adding 2μg/ml of antibodies and 10μl of protein G-Sepharose
beads (GEHealthcare) to 1ml of the lysate. After a 2-h incubation
at 4◦C under constant agitation, the beads were washed five times
in lysis buffer. The immunoprecipitates were separated by 5–15%
SDS-polyacrylamide gel electrophoresis under non-reducing con-
ditions and transferred to a PVDF membrane (Amersham).
Western blotting on immunoprecipitates was performed using
biotinylated Ts29.2 and a Alexa Fluor 680-labeled streptavidin
(Invitrogen) which was revealed with the Odyssey equipment.
EFFECT OF Ts29.2 mAb ON CELL GROWTH AND APOPTOSIS IN VITRO
Cells in complete FCS medium were distributed into 6 well
plates at 20,000 cells/well. Cells were divided into three groups
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with 0, 10, and 50μg/ml of Ts29.2. Cell counts were performed
in duplicated wells at 24, 48, and 72 h. At 72 h, apoptotic cells
were also quantified by flow cytometry using propidium iodide
(PI, Sigma). After overnight fixation in ethanol 70% at −20◦C,
PI at 50μg/ml was added and apoptosis was measured by
counting cells with sub-G1 DNA content. Statistical analysis were
performed using GraphPad Prism software. Repeated measure
ANOVA was used for comparison between the 3 groups and
calculation of the p-value.
IN VIVO EXPERIMENTS
Balb/c nude mice were injected with 5–10.106 tumor cells subcu-
taneously in the back on day 0. For SW480, when indicated, each
mouse was implanted with the Co-029 weakly expressing SW480
cell line on one side and with the corresponding transduced
Co029 cell lines on the right side. Mice were divided between
treatment and control groups, each group comprising 5 mice.
The treated mice were given the Ts29.2 mAb as follows: a first
injection of 2mg of antibody was given intraperitoneally on day
0 and 1mg was given intraperitoneally twice a week, generally for
4 weeks. Other schedules were tested, single early injection for
SW480-Co029 tumors, or delayed treatment for HT29 tumors
as reported in the Results Section. Control mice received the
same volume of PBS intraperitoneally. The size of the tumor was
determined with the formula (π/6 × length × width × thick-
ness). U-Mann-Whitney test was performed for data analysis.
Experiments were conducted according to the French veterinary
guidelines and those formulated by the European Commission for
experimental animal use (L358-86/609EEC) and were approved
by Inserm (National Institute for health and medical research,
France).
BIOLOCALIZATION
Tumors in nude BALB/c mice were induced by subcutaneous
injection of 107 tumor Isreco-Co029 or SW480-Co029 cells.
After 10 days, 4 mice were injected intraperitoneally with 1mg
Ts29.2mAb. Two mice were sacrificed by cervical dislocation at
24 and 48 h after injection of the mAb. Tumors were excised and
included in tissue freezing medium (Tissue-Tek, Sakura Finetek
Europe) and immediately frozen in liquid nitrogen vapors. Frozen
sections were stained using anti-mouse Alexa 488 labeled goat
antibodies (Molecular Probes, USA) to detect the presence of
mAb in the tumors.
HISTOPATHOLOGY AND IMMUNOHISTOCHEMISTRY FOR
ANGIOGENESIS, APOPTOSIS AND PROLIFERATION ANALYSIS
Following fixation of the tumors in 4% paraformaldehyde,
paraffin sections (4μm thick) were prepared. For pathologi-
cal examination, sections were stained with hematoxylin and
eosin. Immunohistochemistry for anti-CD34 positive murine
endothelial cells (HyCult biotechnology b.v., The Netherlands)
was performed after xylene treatment and rehydration of paraf-
fin sections. Heat-induced epitope retrieval was achieved with
pH8 Tris-EDTA at 98◦C for 30min. Endogenous peroxidase activ-
ity was quenched by 3% H2O2 for 10min. The sections were
placed in coverplates (Shandon, U.S) and incubated with block-
ing serum Biogenex 1:20 (San Ramon, Ca) for 10min. This step
was followed by incubation with anti-mouse CD34 1:20 diluted
in blocking serum 1:10 during 1 h. Slides were then incubated
with a rabbit anti-rat 1:400 (Southern Biotech., Al., USA) diluted
in blocking serum 1:10. The following step consisted in a Rabbit
PowerVision kit (ImmunoVision Technologies, Ca) 20min and
DAB 10min. Slides were counterstained with Mayer’s hema-
toxilin and mounted (Pertex). Quantification of positive vessels
was assessed with a method combining a dedicated slide scan-
ner and a computer-assisted image analysis (Kim et al., 2003).
The positive signal was expressed by the area fraction of stained
endothelial cells within the tumor compared to the whole sur-
face of the tumor, selecting only viable tissue. This procedure
was achieved using Pix-Cyt, a software package designed by the
Groupe Régional d’Etudes sur le Cancer, Centre François Baclesse,
Caen. The same protocol was used for quantifying cells expressing
activated caspase 3. An antihuman activated caspase 3 antibody
was used at 1:100 (Cell Signaling, Ozyme, France). The mitotic
index was calculated as the percentage of mitotic figures per total
tumor cells in two separate fields for each HES stained slides of
HT29 tumors. At least 1000 cells were counted for each tumor.
U-Mann-Whitney test was performed for data analysis.
RESULTS
GENERATION OF ISRECO1 AND SW480 COLON CARCINOMA CELL
LINES EXPRESSING Co-029/tspan8
For in vitro and in vivo studies, the Co-029/tspan8 negative
Isreco1 and SW480 cells were transduced with lentiviral vec-
tors in order to obtain an expression of Co-029/tspan8 similar
to HT29 cells and metastatic cell line Isreco2 (Greco et al.,
2010) (Figure 1A). The specificity of Ts29.2 as compared to the
previously used Ts29.1 mAb was further checked by immunopre-
cipitation and western blot (Figure 1B).
EFFECT OF Ts29.2 mAb ON CELL PROLIFERATION AND APOPTOSIS IN
VITRO
SW480 and SW480-Co029 cells were seeded at 20000/well in 6
well culture plates. After 12 h to let cells adhere to the plates,
Ts29.2 mAb was added at concentrations of 10 and 50μg/ml. Cell
counts were performed 24, 48, and 72 h later. No difference in
proliferation was observed between SW480, SW480-Co029, and
HT29 cells cultured in the presence or absence of Ts29.2 mAb
(Figure 2). Results shown are representative of 2 experiments. An
absence of effect on proliferation was also observed for Isreco1
and Is1-Co029 cells (data not shown). At 72 h, an apoptosis test
was performed that showed a proportion of apoptotic cells below
5%, similar between control and antibody treated cells (data not
shown).
BIOLOCALIZATION OF Ts29.2 mAb IN XENOGRAFTS
Localization of the mAb into the tumor is a requirement for its
use for therapeutic purpose. Therefore, we analyzed intratumoral
distribution after i.p. injection of 1mg Ts29.2 mAb in mice car-
rying previously untreated tumors. Frozen sections of tumors
excised at 24 and 48 h after mAb injection were scored for mAb
influx by immunofluorescent staining. A weak diffuse extracellu-
lar labeling was seen in SW480 tumors. An intense surface label-
ing was detectable only on Co-029/tspan8 expressing tumor cells
(Figure 3A). The antibody was also detected in liver sinusoids
(Figure 3B). Similar aspects were observed at 24 and 48 h.
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FIGURE 1 | Co-029/tspan8 recognition by mAb Ts29.2. (A) Expression of
Co-029/tspan8 by transduced cell lines Isreco1 and SW480 as compared to
HT29 cell line. A similar level of expression was obtained after transduction
compared to endogenous expression of HT29 cells. SW480 cells have a
low endogenous expression of Co-029/tspan8. Negative isotypic controls of
Isreco1 and Is1-Co029 are not shown because they are at the same level as
Isreco1 labeled with Ts29.2mAb. Mean Fluorescence Intensity values
appear directly on the graphs (B) Western blot with biotinylated-Ts29.2
mAb of cell extracts immunoprecipitated by Ts29.1 (previously Ts29) or
Ts29.2.
EARLY TREATMENT OF TUMORS WITH MULTIPLE INJECTIONS OF
Ts29.2 mAb
Ten Balb/c nude mice were injected with 107 tumor cells subcu-
taneously on the back, on the left side for SW480 cells and on the
right side for SW480-Co029 cells and the treatment was imme-
diately started. SW480 tumors grew rapidly and already at day
14, a clear inhibition of growth of SW480-Co029 tumors in the
Ts29.2 treated group was observed as compared to the PBS con-
trol groups. Globally, the reduction of growth was above 70%.
Growth of SW480 tumors was similar in PBS and Ts29.2 treated
FIGURE 2 | Effect of Ts29.2 mAb on cell proliferation. Ts29.2 mAb has
no effect on cell proliferation at 10 or 50μg/ml on cells expressing either a
low or a high level of tetraspanin Co-029/tspan8.
groups and the mean size was slightly inferior to PBS treated
SW480-Co029 tumors (Figures 4A,B).
Nude mice were also injected with Is1-Co029 tumor cells and
treated according to the same protocol. Tumor growth was much
slower than for SW480 tumors and measurements started at day
42.However, a similar inhibition linked to antibody treatment was
observed (Figure 4C). The expression of Co-029/tspan8 did not
change significantly the tumor growth pattern (data not shown).
The endogeneously Co-029/tspan8 expressing HT29 cells grew
very fast in nude mice. Two groups of five mice were injected
with 5.106 cells subcutaneously and the same treatment protocol
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FIGURE 3 | Detection of the TS29.2 mAb in vivo 24h after injection.
(A) SW480-Co029 tumor cells are strongly labeled. This labeling appears
to be predominantly membranous (arrows). PBS is shown as negative
control. In SW480 tumors, a weaker staining with a diffuse interstitial
labeling is visible showing that the mAb penetrates inside the tumor. (B)
Due to the presence of circulating Ts29.2 mAb sinusoids are labeled in
the liver of injected nude mice. PBS is shown as negative control. Scale
bar 10μm.
was applied. An inhibition of 50% of tumor growth was observed
(Figure 5A).
Interestingly, the expression of Co-029/tspan8 did not change
the in vivo growth of PBS treated SW480 tumors (Figure 4B) or
Isreco1 tumors (data not shown).
Histological examination showed encapsulated tumors with
large areas of necrosis in all tumors (Figure S1) whose general
aspect did not differ between Ts29.2 mAb and PBS treated mice
(Figure S2). Moreover, no significant infiltration by inflammatory
cells could be noticed in Ts29.2 treated mice as compared to PBS
controls, whether the cells expressed Co-029/tspan8 or not. This
picture differed from what was observed in tumors implanted in
nude mice in which a strong ADCCwas observed following injec-
tion of a mAb of IgG2a subclass, a subclass with strong ADCC
activity. These tumors were essentially necrotic with the presence
of large foamy macrophages (Adams et al., 1984).
TREATMENT OF TUMORS WITH A SINGLE INJECTION OF mAb
In order to determine if the early injection of 2mg Ts29.2 mAb
could inhibit tumor implantation, two groups of five mice were
treated with a single dose of Ts29.2 mAb at the time of SW480-
Co-029/tspan8 tumor implantation. No difference was noticed
between tumors treated with Ts29.2 or PBS indicating that a sus-
tained treatment is required for an observable effect and that an
effect on tumor implantation cannot be invoked for inhibition of
tumor growth (data not shown).
DELAYED TREATMENT OF TUMORS
The effect of delayed treatment with Ts29.2 mAb on HT29 tumor
growth was also evaluated. For that purpose, 25 nude mice were
injected with 5.106 cells on day 0. On day 10, 10 mice with tumors
of similar size were selected and separated in 2 groups. One group
was injected with 2mg Ts29.2 followed by injections of 1mg twice
a week for 2 weeks while the other group of mice received con-
trol PBS injections. An inhibition of growth of 40%, slightly lower
than with the early starting treatment (Figure 5A), was observed
(Figure 5B).
ANGIOGENESIS, APOPTOSIS, AND PROLIFERATION IN VIVO (FIGURE 6)
In order to check for an effect of Ts29.2 mAb on tumor angio-
genesis as was reported for an anti-rat Co-029/tspan8 mAb (Claas
et al., 1998; Gesierich et al., 2006), we analyzed vascular density by
CD34 labeling and image analysis. No significant differences were
observed between Ts29.2 HT29 in vivo treated tumors and con-
trols (Figures 6A,B). Similarly, in situ quantification of apoptosis
by activated caspase 3 labeling did not show a difference between
PBS and Ts29.2 treated HT29 (Figures 6A,C) or SW480-Co029
tumors (not shown). However, an effect of Ts29.2 on cell prolifer-
ation was detected since the mitotic index was 1.71% ± 0.31% in
the tumors cells of Ts29.2 treated mice whereas it was 3% ± 0.4%
for PBS treated mice (p = 0.027) (Figure 6A).
DISCUSSION
This work shows that an IgG2b mouse mAb toward human
tetraspanin Co-029/tspan8 slows down significantly growth of
colorectal tumors in vivo in a xenogeneic nude mice model.
Tetraspanins are membrane proteins forming a 33 family
members whose function has not been elucidated apart from
their ability to form large multimolecular membrane complexes,
the “tetraspanin web” (or tetraspanin enriched microdomains)
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FIGURE 4 | Effect of Ts29.2 mAb treatment on tumor growth in vivo. (A)
A clear inhibition of SW480-Co029 growth is visible (arrow) in the mouse
treated with Ts29.2mAb as compared to SW480 tumor (right) or tumors in PBS
treated mice (left). (B) Growth curves of SW480-Co029 tumors in nude mice
compared to tumors treated with PBS or SW480 cells expressing a low level
of Co-029/tspan8. First and last injections of Ts29.2 mAb or PBS are indicated
below. (C) Growth curves of Is1-Co029 tumors in nude mice treated with
Ts29.2mAb. First and last injections of Ts29.2mAb or PBS are indicated below.
FIGURE 5 | Initial and delayed treatments of HT29 tumors in nude mice.
(A) Treatment started at day 0. An inhibition of 50% was observed after 4
weeks of Ts29.2 mAb injections. First and last injections of Ts29.2mAb or
PBS are indicated below. (B) Same experiment but injections of Ts29.2 mAb
started at day 10 after tumor implantation. A lower inhibition (40%) was
observed. First and last injections of Ts29.2 mAb or PBS are indicated below.
and for their control over traffic or function of some associ-
ated molecules (Hemler, 2003; Charrin et al., 2009). A relation
between tumor prognosis and the level of expression of several
tetraspanins has been widely reported, either in patients or exper-
imentally, in numerous tumors (Boucheix and Rubinstein, 2001;
Charrin et al., 2009; Zoller, 2009; Romanska and Berditchevski,
2011; Hemler, 2013) while opposite effects have been described
depending on the tetraspanin studied. As a matter of fact, the way
the expression of a tetraspanin may affect the course of a tumor
remains widely unknown and may differ from one tetraspanin
to another. It is hypothesized that tetraspanin effects are medi-
ated by molecular partners within the “tetraspanin web.” Among
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FIGURE 6 | In vivo effect of HT29 tumors treatment with Ts29.2
antibodies. (A) Quantification of angiogenesis (CD34 vascular labeling),
apoptosis (activated caspase 3 labeling) and proliferation (mitotic index). (B)
DAB stained vessels are clearly seen within neighboring tumor areas. (C)
The DAB stained cells are easily distinguished from neighboring tumor
areas. No difference is seen between the mAb Ts29.2 treated tumor (left)
and the PBS treated tumor (right) in (B,C). Scale bar 50μm.
tetraspanins that were reported as modulators of tumor pro-
gression, CD82 is considered as a metastasis suppressor gene
(Dong et al., 1995) and associated with favorable prognosis
through an inhibitory effect on cell motility and invasiveness.
High CD9 expression has also mostly been associated with a
favorable prognosis for patients and reduced metastasis in ani-
mal models (Ikeyama et al., 1993; Boucheix et al., 2001; Zoller,
2009). Also, intratracheal administration of adenovirus encoding
eitherMRP-1/CD9 or KAI1/CD82 into lung tumors-bearingmice
reduced metastasis to the mediastinal lymph node (Takeda et al.,
2007). There is even a synergy in simultaneous reduction of CD9
and CD82 that leads to increased metastatic potential in breast
cancer (Huang et al., 1998). On the other hand high levels of
tetraspanins CD151 and Co-029/tspan8 are associated with poor
prognosis (Zoller, 2009; Greco et al., 2010). Possible mechanisms
for a role of CD151 overexpression in tumor progression may
come from an enhancement of Rac and cdc42 activation (Shigeta
et al., 2003) and an effect of integrin-mediated tumor cell motil-
ity via FAK activation (Kohno et al., 2002). Only few experiments
with tetraspanin knockout mice were reported but confort pre-
vious experimental and clinical data. In the TRAMP (Transgenic
adenocarcinoma of mouse prostate) model, genetic ablation of
the tetraspanins Cd9 and Cd151 did not affect prostate tumor ini-
tiation butCd151 ablation reduces spontaneous metastatic spread
whereas ablation of the tetraspanin Cd9 increases spontaneous
metastases, in an organ specific manner in both cases (Copeland
et al., 2013a,b).
Co-029/tspan8 protumoral properties have been clearly shown
by Zoller and coworkers (Gesierich et al., 2006) in a rat model of
pancreatic tumor. In vitro rat Co-029/tspan8 has been shown to
promote motility through its association with α6β4, to increase
apoptosis resistance and in an in vivo hepatoma model to pro-
mote liver metastasis (reviewed in Zoller, 2009). Conversely, in
the absence of integrin α6β4, the rat tspan8 D6.1A, appears to
be a strong inducer of angiogenesis. In this model, the angiogenic
effect appears to be mediated by tumor cells exosomes that recruit
tspan8 together with other tetraspanins like CD9 or CD151 and
associated molecules (Nazarenko et al., 2010). In our model of
colorectal Co-029/tspan8 transduced tumor cell lines, we were
not able to demonstrate a direct effect of Co-029/tspan8 on cell
motility on collagen I (Greco et al., 2010). However, such an effect
became apparent in vitro after silencing of E-cadherin, p120ctn
or RhoA in Isreco cell lines. By crosslinking, we have shown that
Co-029/tspan8 may associate with E-cadherin thus providing a
molecular basis for this observation. In nude mice, the growth of
Isreco1 or SW480 tumors and their corresponding Co-029/tspan8
transduced cell lines was either identical or not significantly dif-
ferent. In this context, analysis of vascular density didn’t appear
to be reduced in Ts29.2 mAb treated tumors compared to PBS
treated tumors.
Concerning the in vivo effect of the mouse anti Co-029/tspan8
IgG2b Ts29.2, the inhibition of tumor growth occurs without
toxic effect of the mAb on cells in vitro and in the absence at
histological level of inflammatory cells infiltration in the tumor.
Moreover, no significant increase of activated caspase 3 label-
ing was observed in HT29 treated tumors. This is in agreement
with early observations that mouse IgG2b, as opposed to IgG2a,
are considered as being poor mediators of ADCC in nude mice
(Herlyn and Koprowski, 1982; Anasetti et al., 1987). However,
we can’t completely exclude a limited recruitment of effector cells
that could be demonstrated by cellular dissociation of the tumors.
Finally, since we could not demonstrate an effect on angiogen-
esis in Ts29.2 mAb treated mice another mechanism should be
operating. These negative results contrast with another model of
gastric tumor implantation in SCID mice treated with the mAb
ALB6 (IgG1) directed against tetraspanin CD9 that resulted in
inhibition of tumor growth associated with increased apopto-
sis and reduced angiogenesis (Nakamoto et al., 2009). On the
other hand, the in vivo inhibition of proliferation assessed by
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the mitotic index in contrast to the absence of in vitro effect
places an indirect functional effect of the mAb Ts29.2 on tumor
growth among the likely hypotheses. Considering the role of
tetraspanins in the assembly of cell surface multimolecular com-
plexes containing various molecules such as integrins or growth
factor receptors, signalization through these molecules appears
as a possible target. An effect of tetraspanins on growth factor
receptor signalization was already reported in vitro for CD82 that
negatively regulates EGFR (Odintsova et al., 2000) but remains to
be demonstrated for Co-029/tspan8. In addition, the MAP kinase
pathway is already engaged due to the KRAS or BRAF mutations
in the tumor cell lines used in this work. Therefore, as far as EGFR
could be involved, an effect through another pathway as the PI3K-
Akt pathway should be considered. Alternatively different growth
factor receptors of the Erb family or other growth factor recep-
tors like c-Met (Takahashi et al., 2007) could be turned on or
regulated. The tetraspanin CD151 has also been tested as target
of anti-tumor antibodies in animal models (reviewed in Haeuw
et al., 2011). An inhibition of tumor growth has been observed
in vivo with selected antibodies but the mechanism remains to
be determined. Of interest is the inhibition by CD151 antibodies
of tumor cell intravasation and metastasis formation in the chick
embryo (Zijlstra et al., 2008).
To our knowledge, among tetraspanins, only CD37 has been
targeted in human malignancies (Press et al., 1989; Sala-Valdes
et al., 2012). An 131I conjugated mouse CD37 mAb was shown to
induce complete remission in 6/6 patients with B cell lymphoma
(Kaminski et al., 1993). Several humanized CD37 genetically
engineered antibodies are currently under investigation for clin-
ical applications (Heider et al., 2011; Krause et al., 2012). Their
effects are mediated by apoptosis induction, ADCC (Heider et al.,
2011) or direct cell death (Krause et al., 2012; Lapalombella et al.,
2012).
Even in the absence of a clear mechanism for growth inhibition
by Ts29.2mAb, we propose that the tetraspanin Co-029/tspan8
can be an appropriate target for treatment of some epithelial
tumors, especially colorectal tumors. The reasons are that it is a
membrane protein for which antibodies are available, that its tis-
sue distribution is restricted and that its increased expression is
linked to a bad prognosis. Among tetraspanins and apart from
CD37 in B cell malignancies, Co-029/tspan8 is one of the best
candidates since other tetraspanins like CD9, CD82, or CD151
have a much wider tissue distribution. Toxicity of the biolog-
ical drug may result from the destruction of normal cells and
too much expression on normal tissues may trap the mAb and
prevents its binding to tumor tissues.
Finally, the efficiency of the mAb could be considerably
improved by replacing the Fc fragment with already available
sequences and the immunization risk could be alleviated by
humanization of the molecule. For all these reasons, targeting
the tetraspanin Co-029/tspan8 is worth further developments in
order to determine if it would be an efficient addition to currently
available treatments of digestive tumors.
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